The aim of this post hoc analysis was to assess the efficacy and safety of filgotinib in combination with MTX in the subgroup of patients from the FINCH 1 trial with moderately active RA and an inadequate response to MTX, based on DAS28-CRP >3.2 to ≤5.1 at baseline. The gene discussed is CRP; the disease is rheumatoid arthritis.